Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

PubMed  Google Scholar 

Beal EW, Tumin D, Moris D, et al. Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2018;7(4):270–6.

Article  PubMed  PubMed Central  Google Scholar 

Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol. 2016;23(1):235–43.

Article  PubMed  Google Scholar 

Amini N, Ejaz A, Spolverato G, et al. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol. 2014;110(2):163–70.

Article  PubMed  Google Scholar 

Kubo S, Shinkawa H, Asaoka Y, et al. Liver cancer study group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma. Liver Cancer. 2022;11(4):290–314.

Article  PubMed  PubMed Central  Google Scholar 

Nagino M, Hirano S, Yoshitomi H, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition. J Hepatobiliary Pancreat Sci. 2021;28(1):26–54.

Article  PubMed  Google Scholar 

Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.

Article  PubMed  Google Scholar 

Burris HA 3rd, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25(5):626–35.

Article  PubMed  Google Scholar 

Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853–65.

Article  PubMed  Google Scholar 

Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–84.

Article  PubMed  PubMed Central  Google Scholar 

Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS ONE. 2014;9(12):e115383.

Article  PubMed  PubMed Central  Google Scholar 

Chakrabarti S, Kamgar M, Mahipal A. Targeted therapies in advanced biliary tract cancer: an evolving paradigm. Cancers (Basel). 2020;12(8):2039.

Article  PubMed  Google Scholar 

Rizzo A, Ricci AD, Brandi G. Pemigatinib: hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun. 2021;27:100337.

PubMed  Google Scholar 

Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–85.

Article  PubMed  Google Scholar 

Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228–39.

Article  PubMed  Google Scholar 

Inada H, Miyamoto H, Shinriki S, et al. Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer. Int J Clin Oncol. 2024;29(12):1908–15.

Article  PubMed  Google Scholar 

Ando K, Nakamura Y, Kitao H, et al. Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study). Br J Cancer. 2023;129(6):1032–9.

Article  PubMed  PubMed Central  Google Scholar 

Wang H, Shan Q, Guo J, et al. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab. Lung Cancer. 2021;151:76–83.

Article  PubMed  Google Scholar 

Zhu M, Kim J, Deng Q, et al. Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden. Cancer Cell. 2023;41(10):1731-1748.e8.

Article  PubMed  PubMed Central  Google Scholar 

Wang C, Tan JYM, Chitkara N, Bhatt S. TP53 mutation-mediated immune evasion in cancer: mechanisms and therapeutic implications. Cancers (Basel). 2024;16(17):3069.

Article  PubMed  Google Scholar 

Wolf EM, Fingleton B, Hasty AH. The therapeutic potential of TREM2 in cancer. Front Oncol. 2022;2(12):984193.

Article  Google Scholar 

Lei X, Gou YN, Hao JY, Huang XJ. Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression. Front Oncol. 2024;25(14):1375729.

Article  Google Scholar 

Cui T, Sun L, Guo X, et al. Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response. J Hepatol. 2025;S0168–8278(25):00231–4.

Google Scholar 

Chasov V, Zaripov M, Mirgayazova R, et al. Promising new tools for targeting p53 mutant cancers: humoral and cell-based immunotherapies. Front Immunol. 2021;13(12):707734.

Article  Google Scholar 

Pham D, Tan X, Balderson B, et al. Robust mapping of spatiotemporal trajectories and cell-cell interactions in healthy and diseased tissues. Nat Commun. 2023;14(1):7739.

Article  PubMed  PubMed Central  Google Scholar 

Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(2):259–71.

Article  PubMed  Google Scholar